Skip to content
SW London Integrated Medicines Optimisation Committee

Main Navigation

  • Home
  • About us
  • Your area
    • Croydon
  • Policies
    • Commissioning
    • Hospital specialist only drugs list
    • Information for patients
    • Interface prescribing policy
    • Position statements
    • Self care guidance for clinicians
    • Shared care prescribing guidelines and transfer of care agreements
  • Clinical Guidance
    • Cardiovascular
    • COVID-19
    • Dermatology
    • Diabetes
    • Gastroenterology
    • Growth hormone
    • Haematology
    • Interim sequential biologics policy
    • Mental health
    • Neurology
    • Ophthalmology
    • Oral nutritional supplements
    • Respiratory
    • Rheumatology
    • Stoma care
    • Urology
    • Urogynaecology
    • Tofacitinib- MHRA safety implementation
    • Wound Care
  • IFR
  • Contact us
  • Cardiovascular
  • COVID-19
  • Dermatology
  • Diabetes
    • Continuous and Flash Glucose Monitoring
    • Type 2 Diabetes and frailty
  • Gastroenterology
  • Growth hormone
  • Haematology
  • Interim sequential biologics policy
  • Mental health
  • Neurology
  • Ophthalmology
  • Oral nutritional supplements
    • Guidelines
    • Food First Resources
    • Care Homes Resources
  • Respiratory
  • Rheumatology
  • Stoma care
  • Tofacitinib- MHRA safety implementation
  • Urogynaecology
  • Urology
  • Wound Care

Ophthalmology

Choroidal Neovascularisation associated with pathological myopia- SWL Drug Pathway v1.0

Diabetic Macular Oedema- SWL drug pathway v1.0

Retinal Vein Occlusion- SWL Drug pathway v1.0

Wet Age-related Macular Degeneration- SWL drug pathway v1.0

Group managed by ISPS Team
NHS South West London Clinical Commissioning Group
120 The Broadway
Wimbledon SW19 1RH
  • Privacy policy
  • Cookie policy
  • Google Translate
Site designed by NECS Design Solutions